Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Nov 3;9(6):pkaf096.
doi: 10.1093/jncics/pkaf096.

Utility of metastasis-directed radiotherapy with and without hormonal therapy in management of oligometastatic prostate cancer

William S Chen  1   2 , Abuzar Moradi Tuchayi  3 , Ali Sabbagh  1 , Inkyu Kim  1 , Evan Porter  1 , Amir Ashraf-Ganjouei  1 , Yun Rose Li  4 , Alon Witztum  1 , Abhejit Rajagopal  3 , Steven N Seyedin  1 , Roxanna Juarez  3 , Peter R Carroll  2 , Felix Y Feng  1   2 , Eric J Small  5 , Thomas A Hope  3 , Julian C Hong  1   6   7
Affiliations

Utility of metastasis-directed radiotherapy with and without hormonal therapy in management of oligometastatic prostate cancer

William S Chen et al. JNCI Cancer Spectr. .

Abstract

Background: Metastasis-directed radiotherapy (MDT) is the mainstay in management of oligometastatic prostate cancer (PCa), and PSMA-PET is currently the most sensitive imaging modality for localizing PCa metastases. The efficacy of MDT guided by PSMA-PET imaging with and without androgen deprivation therapy (ADT) ± androgen-receptor pathway inhibitor (ARPI) has not yet been well characterized. We sought to evaluate the efficacy of PSMA PET-guided MDT.

Methods: This is a single-institutional retrospective study of patients diagnosed with metastatic PCa by PSMA-PET imaging who were treated with MDT. Survival analyses were performed using the Kaplan-Meier method with Cox proportional hazards testing for significance. Cumulative incidence analyses were performed with Gray's testing for significance.

Results: One hundred and ninety-four metastatic lesions from 101 patients identified by PSMA PET were irradiated with MDT. Forty-seven of the 79 (59%) patients with hormone-sensitive PCa (HSPC) received ADT ± ARPI along with MDT. Four of 194 lesions (2.1%) demonstrated radiographic progression after MDT, with a median follow-up of 22.4 months. Two-year cumulative incidence of progression from HSPC to CRPC was 11% in patients who received ADT ± ARPI and 35% in those who did not (P = .027). Median biochemical progression free survival of patients with CRPC, HSPC treated without ADT or ARPI, and HSPC treated with ADT ± ARPI was 5.4, 7.6, and 43.9 months, respectively (P < .0001). No Grade 3-5 adverse effects were observed.

Conclusions: MDT guided by PSMA-PET imaging is well-tolerated and delays biochemical progression in patients with CRPC and HSPC, with a greater effect observed in patients also receiving ADT ± ARPI.

PubMed Disclaimer

Conflict of interest statement

J.C.H., who is a JNCI Cancer Spectrum Associate Editor and co-author on this paper, was not involved in the editorial review or decision to publish the manuscript.

Figures

Figure 1.
Figure 1.
Kaplan-Meier curves demonstrating (A) PFS and (B) OS stratified by hormone-sensitive disease status and receipt of systemic therapy.
Figure 2.
Figure 2.
Cumulative incidence of disease progression from HSPC to CRPC, stratified by receipt of concurrent ADT.
Figure 3.
Figure 3.
Cumulative incidence of in-field progression of disease by imaging.
See this image and copyright information in PMC

References

    1. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13:8-10. - PubMed
    1. Guckenberger M, Lievens Y, Bouma AB, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020;21:e18-e28. - PubMed
    1. Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol. 2020;38:2830-2838. - PMC - PubMed
    1. Gomez DR, Tang C, Zhang J, et al. Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non–small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol. 2019;37:1558-1565. - PMC - PubMed
    1. Ost P, Reynders D, Decaestecker K, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol. 2018;36:446-453. - PubMed

MeSH terms

Substances

LinkOut - more resources